Journal: bioRxiv
Article Title: Pan-cancer N -glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
doi: 10.1101/2024.12.11.627962
Figure Lengend Snippet: (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain IHC data (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.
Article Snippet: Normal tissue IHC data were downloaded from Human Protein Atlas (v.23.0) .
Techniques: Glycoproteomics, RNA Sequencing, MANN-WHITNEY